哥伦比亚心血管疾病患者evolocumab (Repatha®)患者支持计划分析

IF 1.9 Q3 PERIPHERAL VASCULAR DISEASE Clinica e Investigacion en Arteriosclerosis Pub Date : 2023-11-01 DOI:10.1016/j.arteri.2023.04.005
Ángel Alberto García-Peña , Mariana Pineda-Posada , Carol Páez-Canro , César Cruz , Daniel Samacá-Samacá
{"title":"哥伦比亚心血管疾病患者evolocumab (Repatha®)患者支持计划分析","authors":"Ángel Alberto García-Peña ,&nbsp;Mariana Pineda-Posada ,&nbsp;Carol Páez-Canro ,&nbsp;César Cruz ,&nbsp;Daniel Samacá-Samacá","doi":"10.1016/j.arteri.2023.04.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Cardiovascular diseases are considered the leading cause of death globally. This study describes the demographic characteristics, treatment patterns, self-reported compliance and persistence, and to explore variables related to non-adherence of patients enrolled in the cardiovascular patient support program (PSP) for evolocumab treatment in Colombia.</p></div><div><h3>Methods</h3><p>This retrospective observational of the data registry of patients who entered the evolocumab PSP program.</p></div><div><h3>Results</h3><p>The analysis included 930 patients enrolled in the PSP (2017-2021). Mean age was 65.1 (SD<!--> <!-->±<!--> <!-->13.1) and49.1% patients were female. The mean compliance rate to evolocumab treatment was 70.5% (SD<!--> <!-->±<!--> <!-->21.8). A total of 367 patients (40.5%) reported compliance higher than 80%. Persistence analysis included 739 patients (81.5%) where 87.8% of these patients were considered persistent to treatment. A total of 871 patients (93.7%) reported the occurrence of at least one adverse event during the follow-up period (mostly non-serious).</p></div><div><h3>Conclusion</h3><p>This is the first real-life study describing patient characteristics, compliance and continuity of treatment for dyslipidemia in a patient support program in Colombia. The overall adherence found was higher than 70%; similar to findings reported in other real-life studies with iPCSK9. However, the reasons for low compliance were different, highlighting the high number of administrative and medical reasons for suspension or abandonment of treatment with evolocumab.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"35 6","pages":"Pages 280-289"},"PeriodicalIF":1.9000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Análisis del programa de apoyo al paciente de evolocumab (Repatha®) para pacientes con enfermedades cardiovasculares en Colombia\",\"authors\":\"Ángel Alberto García-Peña ,&nbsp;Mariana Pineda-Posada ,&nbsp;Carol Páez-Canro ,&nbsp;César Cruz ,&nbsp;Daniel Samacá-Samacá\",\"doi\":\"10.1016/j.arteri.2023.04.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Cardiovascular diseases are considered the leading cause of death globally. This study describes the demographic characteristics, treatment patterns, self-reported compliance and persistence, and to explore variables related to non-adherence of patients enrolled in the cardiovascular patient support program (PSP) for evolocumab treatment in Colombia.</p></div><div><h3>Methods</h3><p>This retrospective observational of the data registry of patients who entered the evolocumab PSP program.</p></div><div><h3>Results</h3><p>The analysis included 930 patients enrolled in the PSP (2017-2021). Mean age was 65.1 (SD<!--> <!-->±<!--> <!-->13.1) and49.1% patients were female. The mean compliance rate to evolocumab treatment was 70.5% (SD<!--> <!-->±<!--> <!-->21.8). A total of 367 patients (40.5%) reported compliance higher than 80%. Persistence analysis included 739 patients (81.5%) where 87.8% of these patients were considered persistent to treatment. A total of 871 patients (93.7%) reported the occurrence of at least one adverse event during the follow-up period (mostly non-serious).</p></div><div><h3>Conclusion</h3><p>This is the first real-life study describing patient characteristics, compliance and continuity of treatment for dyslipidemia in a patient support program in Colombia. The overall adherence found was higher than 70%; similar to findings reported in other real-life studies with iPCSK9. However, the reasons for low compliance were different, highlighting the high number of administrative and medical reasons for suspension or abandonment of treatment with evolocumab.</p></div>\",\"PeriodicalId\":45230,\"journal\":{\"name\":\"Clinica e Investigacion en Arteriosclerosis\",\"volume\":\"35 6\",\"pages\":\"Pages 280-289\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica e Investigacion en Arteriosclerosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S021491682300044X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica e Investigacion en Arteriosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S021491682300044X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

背景:心血管疾病被认为是全球死亡的主要原因。本研究描述了人口统计学特征、治疗模式、自我报告的依从性和持久性,并探索与哥伦比亚心血管患者支持计划(PSP)中evolocumab治疗的患者不依从性相关的变量。方法回顾性观察进入evolocumab PSP项目的患者的注册数据。结果该分析包括930名参与PSP(2017-2021)的患者。平均年龄为65.1 (SD±13.1)岁,女性占49.1%。evolocumab治疗的平均依从率为70.5% (SD±21.8)。367例患者(40.5%)的依从性高于80%。持续性分析纳入739例患者(81.5%),其中87.8%的患者被认为坚持治疗。共有871例患者(93.7%)报告在随访期间至少发生一次不良事件(多为非严重事件)。结论:这是哥伦比亚患者支持项目中第一个描述血脂异常患者特征、依从性和治疗连续性的现实研究。总体依从性高于70%;与iPCSK9在现实生活中的其他研究结果相似。然而,低依从性的原因各不相同,突出表明暂停或放弃evolocumab治疗的行政和医学原因较多。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Análisis del programa de apoyo al paciente de evolocumab (Repatha®) para pacientes con enfermedades cardiovasculares en Colombia

Background

Cardiovascular diseases are considered the leading cause of death globally. This study describes the demographic characteristics, treatment patterns, self-reported compliance and persistence, and to explore variables related to non-adherence of patients enrolled in the cardiovascular patient support program (PSP) for evolocumab treatment in Colombia.

Methods

This retrospective observational of the data registry of patients who entered the evolocumab PSP program.

Results

The analysis included 930 patients enrolled in the PSP (2017-2021). Mean age was 65.1 (SD ± 13.1) and49.1% patients were female. The mean compliance rate to evolocumab treatment was 70.5% (SD ± 21.8). A total of 367 patients (40.5%) reported compliance higher than 80%. Persistence analysis included 739 patients (81.5%) where 87.8% of these patients were considered persistent to treatment. A total of 871 patients (93.7%) reported the occurrence of at least one adverse event during the follow-up period (mostly non-serious).

Conclusion

This is the first real-life study describing patient characteristics, compliance and continuity of treatment for dyslipidemia in a patient support program in Colombia. The overall adherence found was higher than 70%; similar to findings reported in other real-life studies with iPCSK9. However, the reasons for low compliance were different, highlighting the high number of administrative and medical reasons for suspension or abandonment of treatment with evolocumab.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinica e Investigacion en Arteriosclerosis
Clinica e Investigacion en Arteriosclerosis PERIPHERAL VASCULAR DISEASE-
CiteScore
3.20
自引率
6.20%
发文量
44
审稿时长
40 days
期刊介绍: La publicación idónea para acceder tanto a los últimos originales de investigación como a formación médica continuada sobre la arteriosclerosis y su etiología, epidemiología, fisiopatología, diagnóstico y tratamiento. Además, es la publicación oficial de la Sociedad Española de Arteriosclerosis.
期刊最新文献
Severe hypertriglyceridemias: What is necessary and what is sufficient. Recommendations of the Spanish Arteriosclerosis Society: The diet in cardiovascular prevention - 2024 Update. Assessment of the impact on thrombogenicity of surface modifications on nitinol stents in an in vitro model. Caracterización clínica y detección de arteriosclerosis subclínica en sujetos con hiperalfalipoproteinemia extrema Dietary plant microRNAs as potential regulators of cellular cholesterol efflux
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1